STOCKS TELEGRAPH

Tag: OCGN

  • 20 Trending Stocks In Biotechnology Industry You Should Consider Buying

    20 Trending Stocks In Biotechnology Industry You Should Consider Buying

    Investors are always looking for safe and secure investments and as a strong and profitable industry, the biotechnology industry is considered to be an attractive area of investment. This industry has experienced massive growth in recent years and is continuously adopting new technological advancements to keep pace with the fast-growing market. Biotechnology is a set of tools that uses living organisms to create or change a product, improve plants, trees, or animals, or develop microorganisms for specific uses.

    Modern Biotechnology’s main focus is on medicine. The companies in this sector are involved in the development of new treatments for various complex diseases. Technology has always been at the heart of the biotechnology industry. As the new technologies emerged with the passage of time the efficiency of companies has also improved. Similarly, technological advancements have also changed the clinical trial process.

    There are various other trends that the companies are following. Let see the top 20 companies in the biotechnology industry to get a better view:

    Cassava Sciences Inc. (NASDAQ: SAVA)

    Cassava Sciences Inc. (NASDAQ: SAVA) last closed at $11.47, in a 52-week range of $1.05 to $11.25. Analysts have a consensus price target of $17.00. Cassava Sciences Inc. (SAVA) has earlier announced the results of the Phase 2b study with its drug candidate Sumifilam, in Alzheimer’s disease. The clinical study which has received the funding by the National Institutes of Health (NIH) has shown the improvement in Alzheimer’s disease. Cassava Sciences Inc. (SAVA) market cap has remained high, hitting $242.02 M at the time of writing.

    Inovio Pharmaceuticals Inc. (NASDAQ: INO)

    Inovio Pharmaceuticals Inc. (NASDAQ: INO) stock soar by 10.21% to $16.94. The most recent rating by ROTH Capital, on July 01, 2020, is at a Sell. Inovio Pharmaceuticals Inc. (INO) has revealed that the US Food and Drug Administration (FDA) has informed the company that it has some questions related to the Phase 2/3 trial of its COVID-19 vaccine candidate INO-4800, including its CELLECTRA 2000 delivery device to be used in the trial. the company said that it will halt the trial until it clear all the ambiguities of FDA.

    Sorrento Therapeutics Inc. (NASDAQ: SRNE)

    Sorrento Therapeutics Inc. (NASDAQ: SRNE) Shares headed rising, higher as much as 4.84%. The most recent rating by H.C. Wainwright, on July 31, 2020, is at a Buy. Sorrento Therapeutics Inc. (SRNE) has earlier revealed the results of its’ multicenter, open-label, Phase 1b Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for the Treatment of Intractable Cancer Pain at the 14th Annual Pain Therapeutics Summit. The company has reported the encouraging results from its Phase 1b study to evaluate Epidural Resiniferatoxin Injection.

    Vaxart Inc. (NASDAQ: VXRT)

    Vaxart Inc. (NASDAQ: VXRT) rose 7.40% after gaining more than $0.51 on Friday. Pomerantz LLP is investigating claims on behalf of investors of Vaxart, Inc. Vaxart Inc. share price went from a low point around $0.25 to briefly over $17.49 in the past 52 weeks, though shares have since pulled back to $7.40. Vaxart Inc.’s market cap has remained high, hitting $752.43 M at the time of writing.

    Novavax Inc. (NASDAQ: NVAX)

    Novavax Inc. (NASDAQ: NVAX) stock soar by 10.86% to $113.56. The most recent rating by H.C. Wainwright, on August 06, 2020, is at a Buy. Par Sterile Products, LLC (Par Sterile) has entered into a non-exclusive agreement with Novavax, Inc. to provide fill-finish manufacturing services at its plant in Rochester, Michigan for NVX-CoV2373, Novavax’ COVID-19 vaccine candidate.

    Onconova Therapeutics Inc. (NASDAQ: ONTX)

    Onconova Therapeutics Inc. (NASDAQ: ONTX) Shares headed falling, lower as much as -3.23%. The most recent rating by H.C. Wainwright, on March 01, 2018, is at a Buy. Onconova Therapeutics Inc. (ONTX) earlier revealed that it has started the Phase 1 clinical trial in China for ON 123300 by its partner, HanX Biopharmaceuticals. Onconova has partnered with HanX Biopharmaceuticals in December 2017 for the development, registration, and commercialization of ON 123300 in China.

    Jaguar Health Inc. (NASDAQ: JAGX)

    Jaguar Health Inc. (NASDAQ: JAGX) last closed at $0.31, in a 52-week range of $0.29 to $1.38. Jaguar Health Inc. (JAGX) earlier revealed itis scheduled to participate in its first “Diarrhea Dialogues” virtual event on October 20 from 3:00 PM. The event, open to the financial and business community, will discuss the importance of supportive care for cancer patients as it relates to chronic lower GI tract distress, specifically with regard to debilitating diarrhea experienced as a result of cancer therapy.

    Zogenix Inc. (NASDAQ: ZGNX)

    Zogenix Inc. (NASDAQ: ZGNX) stock drop by -1.46% to $17.50. The most recent rating by Raymond James, on August 25, 2020, is at an Mkt perform. Zogenix Inc. (ZGNX) has revealed the pricing of its offering of $200,000,000 aggregate principal amount of 2.75% convertible senior notes due 2027 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

    Trevena Inc. (NASDAQ: TRVN)

    Trevena Inc. (NASDAQ: TRVN) Shares headed rising, higher as much as 4.04%. The most recent rating by Guggenheim, on September 14, 2020, is at a Buy. Trevena Inc. (TRVN) has earlier participated in three presentations at the virtual 2020 American College of Clinical Pharmacology (ACCP) Annual Meeting. The meetings have taken place from September 21st to 23rd, 2020.

    VBI Vaccines Inc. (NASDAQ: VBIV)

    VBI Vaccines Inc. (NASDAQ: VBIV) last closed at $3.08, in a 52-week range of $0.47 to $6.93. VBI Vaccines Inc. (VBIV) is scheduled to participate in upcoming presentations including Sci-B-Vac: Results on Ph3 Hep B vaccine, Targeting CMV for the development of effective GBM immunotherapy on September 29 and 30, 2020, respectively. It has today participated in the COVID-19 panel discussion on the topic: What existing treatments and vaccine development platforms show promise to control the rate of infection and spread?

    Brickell Biotech Inc. (NASDAQ: BBI)

    Brickell Biotech Inc. (NASDAQ: BBI) Shares headed rising, higher as much as 3.90%. The most recent rating by Lake Street, on August 28, 2020, is at a Buy. Brickell Biotech Inc. (BBI) has revealed that its Japanese development partner, Kaken Pharmaceutical Co., Ltd. has received approval to manufacture and market sofpironium bromide gel, 5% under the brand name ECCLOCK in Japan for the treatment of primary axillary (underarm) hyperhidrosis.

    VYNE Therapeutics Inc. (NASDAQ: VYNE)

    VYNE Therapeutics Inc. (NASDAQ: VYNE) Shares headed falling, lower as much as -6.17%. VYNE Therapeutics Inc. (VYNE) has revealed that the Company will host a physician symposium on AMZEEQ and ZILXI™ on Thursday, October 1, 2020. VYNE market cap has remained high, hitting $271.70-M at the time of writing.

    Acorda Therapeutics Inc. (NASDAQ: ACOR)

    Acorda Therapeutics Inc. (NASDAQ: ACOR) shares were trading up 30.13% at $0.62 at the time of writing on Friday. Acorda Therapeutics Inc. (NASDAQ: ACOR) share price went from a low point around $0.42 to briefly over $3.27 in the past 52 weeks, though shares have since pulled back to $0.62. ACOR market cap has remained high, hitting $22.70M at the time of writing, giving it a price-to-sales ratio of more than 0. If we look at the recent analyst rating ACOR, H.C. Wainwright downgraded coverage on ACOR shares with a Neutral rating.

    Moderna Inc. (NASDAQ: MRNA)

    Moderna Inc. (NASDAQ: MRNA) last closed at $69.47, in a 52-week range of $13.53 to $95.21. Analysts have a consensus price target of $91.90. Moderna Inc. (MRNA) has moved up 413.45% from its 52-weeks low and moved down -327.03% from its 52-weeks high. Looking at its liquidity, it has a current ratio of 17.30. This company’s market capitalization has remained high, hitting $25.72 billion at the time of writing.

    iBio Inc. (AMEX: IBIO)

    iBio Inc. (AMEX: IBIO) rose 7.77% after gaining more than $0.15 on Friday. iBio Inc. (IBIO) share price went from a low point around $0.05 to briefly over $7.45 in the past 52 weeks, though shares have since pulled back to $2.08. iBio Inc. has moved up 4060.00% from its 52-weeks low and moved down -72.08% from its 52-weeks high.  IBIO market cap has remained high, hitting $336.61 M at the time of writing.

    Akebia Therapeutics Inc. (NASDAQ: AKBA)

    Akebia Therapeutics Inc. (NASDAQ: AKBA) rose 0.81% after gaining more than $0.02 on Friday.  In the past 52-weeks of trading, this company’s stock has fluctuated between the low of $2.34 and a high of $13.71. It has moved up 5.98% from its 52-weeks low and moved down -8191% from its 52-weeks high. Looking at its liquidity, it has a current ratio of 2.30. This company’s market capitalization has remained high, hitting $347.50 million at the time of writing.

    Vaccinex Inc. (NASDAQ: VCNX)

    Vaccinex Inc. (NASDAQ: VCNX) stock drop by -1.10% to $1.79. The most recent rating by BTIG Research, on September 23, 2020, is at a Neutral. Vaccinex Inc. (VCNX) share price went from a low point around $1.70 to briefly over $12.23 in the past 52 weeks, though shares have since pulled back to $1.79. VCNX has moved up 5.29% from its 52-weeks low and moved down -85.36% from its 52-weeks high.  VCNX market cap has remained high, hitting $36.19M at the time of writing.

    Ocugen Inc. (NASDAQ: OCGN)

    Ocugen Inc. (NASDAQ: OCGN) rose 2.29% after gaining more than $0.0 on Friday. In the past 52-weeks of trading, this company’s stock has fluctuated between the low of $0.17 and a high of $16.80. It has moved up 78.53% from its 52-weeks low and moved down -98.19% from its 52-weeks high. Looking at its liquidity, it has a current ratio of 3.30. This company’s market capitalization has remained high, hitting $40.03 million at the time of writing.

    9 Meters Biopharma Inc. (NASDAQ: NMTR)

    9 Meters Biopharma Inc. (NMTR) last closed at $0.76, in a 52-week range of $0.37 to $1.22. 9 Meters Biopharma Inc. (NMTR) has moved up 106.59% from its 52-weeks low and moved down -37.33% from its 52-weeks high. Looking at its liquidity, it has a current ratio of 1.30. This company’s market capitalization has remained high, hitting $101.25 million at the time of writing.

    Clovis Oncology Inc. (NASDAQ: CLVS)

    Clovis Oncology Inc. (NASDAQ: CLVS) stock soar by 3.25% to $5.88. The most recent rating by H.C. Wainwright, on May 18, 2020, is at a Buy. Clovis Oncology Inc. (CLVS) share price went from a low point around $2.93 to briefly over $17.37 in the past 52 weeks, though shares have since pulled back to $5.88. CLVS has moved up 100.68% from its 52-weeks low and moved down -66.15% from its 52-weeks high.  CLVS market cap has remained high, hitting $502.33M at the time of writing.

     

  • Stocks to Watch as Positive U.S-China Trade News Drive-up Markets

    Stocks to Watch as Positive U.S-China Trade News Drive-up Markets

    The markets are up this morning driven by news that the U.S and China are making progress in their trade negotiations. According to the U.S trade negotiator Robert Lighthizer and his Chinese colleague, the two countries were fully committed to ensuring that the negotiations turn out successful.

    This reassurance has led to higher appetite for stocks due to the reduced geopolitical risks. According to Naeem Aslam of Avatrade, the possible positive outcome of the trade negotiations between the two largest economies in the world had taken away a major barrier in the global stock markets.

    The news also come at a time when another risk factor to the economy seems to be falling under control. On Sunday the FDA approved the use of blood plasma in the treatment of COVID-19. In the event that it shows widespread effectiveness, then it would be a green light for the world economy to go back to normal. At the same time, hopes of a COVID-19 vaccine are rising by the day.

    Several biopharma companies and academic institutions are in advanced stages in the race for a vaccine. This has added an extra layer of positive sentiment in the market. In this environment of high optimism, stocks with positive news or anticipated positive news are rallying. Some of the top performers ahead of markets are as below:

    Viveve Medical Inc [NASDAQ: VIVE]

    Viveve is a top performer pre-market and is up b 41% at the time of writing. This comes after the company announced that it has positive primary efficacy data from its Stress Urinary Incontinence (SUI) feasibility study that done over 5-months.

    The company also announced that it had got positive results from its in-vivo pre-clinical study that was done to test the company’s new inert sham that would be used in the upcoming PURSUIT trial in the U.S. Commenting on the results, CEO Scott Durbin stated that they believed that the results were in support of the company’s thesis stating that cryogen-cooling had a good therapeutic effect. The results are likely to support this stock through the day.

    Ocugen Inc [NASDAQ: OCGN]

    Ocugen Inc is another top perfumer this morning and is up by 19%. This comes as investors await news from the company about its forward-looking statements. The stock is also buoyed by the fact that an insider recently bought a sizeable amount of the stock.  The company’s founder Shankar Musunari bought $108k worth of stock, an indicator that he has confidence in the company.

    Vivopower International PLC [NASDAQ: VVPR]

    This is another top performer this morning and is up by 18%. This follows the company’s release of its finances for the financial year ending 30th June 2020. The company reported that revenues grew by 12% compared to the last financial year.  The company also reported that gross revenues grew by 28% compared to the last financial year.  This has inspired investor confidence in the stock pre-market.

     

  • Top Gainers as Positive Market Sentiment Grows

    Top Gainers as Positive Market Sentiment Grows

    The markets are up this afternoon buoyed by hopes of a stimulus package and positive news from big pharma. Pfizer Inc [PFE] was surging earlier in the day on news that the company was in talks with Sanofi, Johnson & Johnson, and the European Union for a possible COVID-19 vaccine distribution deal. Though later news seems to indicate that the deal has hit a snag, it has nonetheless helped push optimism in the market.

    Another news driving market sentiment this afternoon is the launch of several IPOs that include that of Rackspace technology [RXT] and East Resources that has closed its IPO raising a gross of $300 million. IPOs at this time show that companies still have faith in the equity markets despite the volatility brought about by the COVID-19 pandemic. In this environment of optimism, there are big winners in individual stocks. Some of the biggest winners this afternoon are as below:

    MediciNova Inc [NASDAQ:MNOV]

    MediciNova Inc is one of the top gainers in the day and is up by 87.06%. The stock has rallied after the company announced that it had entered into a COVID-19 joint venture with BioComo and Mie University Japan. The vaccine will be developed using a human parainfluenza virus type 2 vector. Under the deal, MediNova now has exclusive rights to the development rights to make use of BC-PV for a SARS-Cov-2 vaccine.

    Commenting on the deal, MediNova CEO has stated that they were happy with this partnership as the world rushes to look for a COVID-`19 vaccine or cure. He added that it was interesting that they were looking at it from an intranasal formulation angle because it could help trigger local mucosal immunity.

    Sogou Inc [NYSE:SOGO]

    This is another top gainer this afternoon and is up 47%. The stock’s rally follows the company’s announcement that it would release its Q2 results on August 17th. The stock’s upside momentum is also buoyed by news that Tencent Holdings was looking to buy it out at $9 a share. This has seen the stock gap up and rallies towards the premium valuation that Tencent Holdings has placed on it. The news of a buyout has come at a time when the market is showing positive momentum.

    Ocugen Inc [NASDAQ:OCGN]

    Ocugen Inc is another top gainer in the day. The stock is up by 45% and is gaining. The rally follows news that the company had been given an Orphan Drug Designation by the FDA for RHO mutation gene-therapy treatment called OCU400. The company CEO stated that this was a major step towards a treatment for Retinal Degenerative Disease.

  • 15 Trending Stocks in Biotechnology Industry

    15 Trending Stocks in Biotechnology Industry

    The biggest movers of the 2020 are biotech stocks. Now, the COVID-19 pandemic has put brighter spotlight on the future of healthcare and specially biotech stocks have respond accordingly.

    Innovative biotech business have adopted the change and are competing to make what could become a life-saving treatment for millions in the form of a vaccine.

    Some of the biggest winners of this transformative mega-trend are discussed below.

    Genocea Biosciences Inc. (NASDAQ:GNCA) shares were trading up 24.44% at $4.48 at the time of writing on Friday.

    Genocea Biosciences Inc. (NASDAQ:GNCA) share price went from a low point around $1.10 to briefly over $3.86 in past 52 weeks, though shares have since pulled back to $4.48. GNCA market cap has remained high, hitting $99.50M at the time of writing, giving it price-to-sales ratio of more than 110.

    If we look at the recent analyst rating GNCA, SVB Leerink initiated coverage on GNCA shares with an Outperform.

    Arbutus Biopharma Corporation (ABUS) last closed at $4.96, in a 52-week range of $0.82 to $6.48. Analysts have a consensus price target of $5.00.

    Ocugen Inc. (OCGN) stock soar by 32.85% to $0.38.

    Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Shares headed falling, lower as much as -3.97%. The most recent rating by ROTH Capital, on April 18, 2019, is at a Buy.

    Capricor Therapeutics Inc. (NASDAQ:CAPR) rose 29.31% after gaining more than $1.75 on Friday.

    Ampio Pharmaceuticals Inc. (AMPE) last closed at $0.96, in a 52-week range of $0.26 to $0.97.

    iBio Inc. (IBIO) last closed at $5.50, in a 52-week range of $0.05 to $7.45.

    Novan Inc. (NOVN) stock soar by 6.06% to $0.86. The most recent rating by Piper Jaffray, on January 06, 2020, is at a Neutral.

    Onconova Therapeutics Inc. (NASDAQ:ONTX) Shares headed falling, lower as much as -2.63%. The most recent rating by H.C. Wainwright, on March 01, 2018, is at a Buy.

    Actinium Pharmaceuticals Inc. (AMEX:ATNM) rose 7.45% after gaining more than $0.03 on Friday.

    Sesen Bio Inc. (SESN) last closed at $0.99, in a 52-week range of $0.37 to $1.54.

    VistaGen Therapeutics Inc. (VTGN) stock drop by -4.39% to $0.76. The most recent rating by Maxim Group, on June 27, 2018, is at a Buy.

    Qualigen Therapeutics Inc. (NASDAQ:QLGN) Shares headed rising, higher as much as 11.22%.

    PolarityTE Inc. (NASDAQ:PTE) rose 10.56% after gaining more than $0.17 on Friday.

    Matinas BioPharma Holdings Inc. (MTNB) last closed at $0.96, in a 52-week range of $0.49 to $2.49.